About the Company
GT Biopharma, Inc.
BUSINESS DESCRIPTION
GT Biopharma, Inc. (NASDAQ: GTBP) is a clinical stage immuno-oncology company focused on developing innovative therapies based on the Company's proprietary NK cell engager (TriKE®) technology....
GT Biopharma News
-
GT Biopharma to Participate in the 10th Anniversary of the Innate Killer Summit...
03/04/2025 12:00 PMSAN FRANCISCO, CALIFORNIA, March 04, 2025 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company fo...
-
GT Biopharma Announces Exercise of Warrants...
02/25/2025 07:00 PMSAN FRANCISCO, CALIFORNIA, Feb. 25, 2025 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company foc...
-
GT Biopharma Announces Request for Withdrawal of Form S-1 Registration Statement...
02/25/2025 12:00 PMSAN FRANCISCO, CALIFORNIA, Feb. 25, 2025 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company foc...
-
GT Biopharma Announces First Patient Dosed in Phase 1 Trial of GTB-3650, Second-...
01/27/2025 12:00 PMInitial data from the Phase 1 trial expected in 2025 SAN FRANCISCO, CALIFORNIA, Jan. 27, 2025 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ...
-
GT Biopharma Reports Third Quarter 2024 Financial Results...
11/14/2024 09:00 PMGTB-3650 TriKE® Phase 1 trial first patient dosed expected in Q4 2024; initial clinical data expected in Q2 2025GTB-5550 TriKE® IND submission for treatment o...
-
GT Biopharma to Participate in the 3rd Annual ROTH Healthcare Opportunities Conf...
09/26/2024 01:15 PMSAN FRANCISCO, CALIFORNIA, Sept. 26, 2024 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company fo...
-
GT Biopharma to Host Virtual KOL Event Showcasing its NK Cell Engager Pipeline a...
09/24/2024 01:15 PMSAN FRANCISCO, CALIFORNIA, Sept. 24, 2024 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company fo...
-
GT Biopharma Reports Second Quarter 2024 Financial Results and Provides Corporat...
08/14/2024 08:05 PMGTB-3650 TriKE® Phase 1 trial initiation expected in 2H 2024; initial clinical data expected in 1H 2025GTB-5550 TriKE® IND submission for treatment of B7H3 po...
-
GT Biopharma Announces FDA Clearance of Investigational New Drug (IND) Applicati...
06/27/2024 01:15 PMGTB-3650 Phase 1 trial initiation expected in H2 2024; initial clinical data expected in H1 2025GTB-5550 TriKE® IND submission for treatment of B7H3 positive s...
Disclaimer: